Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People with breast cancer who have received at least one prior chemotherapy treatment (either before surgery, after surgery, or for advanced/spread disease), and hormone therapy if their cancer is hormone receptor positive
• People with a specific type of ovarian, fallopian tube, or peritoneal cancer (high-grade) who have received at least one prior platinum-based chemotherapy for advanced disease
• People with prostate cancer that has spread and no longer responds to hormone treatment, who are still on hormone-suppressing therapy, have received a newer hormone-blocking drug, and have had up to one prior chemotherapy using taxane drugs
• People with pancreatic cancer who have received at least one prior first-line treatment
• People whose general health and activity level meets a specific standard — meaning they are fully active or have only minor limitations in physical activity (confirm with trial site)
• People with adequate kidney, liver, and blood function
• People with a life expectancy of at least 12 weeks
• People whose cancer can be measured or tracked using standard imaging measurements and/or specific blood markers (such as CA125 or PSA)
• People who have a specific type of inherited or acquired gene mutation affecting DNA repair (known as HRR gene mutations)
• People who have received up to one prior treatment that included a type of drug called a PARP inhibitor
• People with brain metastases (cancer that has spread to the brain) that are either untreated but do not need immediate treatment, or have been previously treated
• People of childbearing potential (female or male) who agree to use effective contraception from the start of the study until 6 months after the last dose of the study drug

Who may not be able to join:

• People who have received any other experimental or approved cancer treatment within 28 days before starting the study drug
• People who have previously received a specific type of PARP inhibitor that selectively targets PARP1
• People whose heart's electrical activity (measured by an ECG) falls outside a specific range — specifically a QTcF reading above 470 ms or below 340 ms (confirm with trial site)
• People with an active hepatitis B or hepatitis C infection
• People with any known condition that increases the risk of bleeding
• People who are unable to swallow tablets or capsules, or who have conditions affecting how the body absorbs medication through the digestive system
• People with any untreated brain lesion larger than 2.0 cm
• People who are currently using steroid medications (such as prednisone) to manage brain metastasis symptoms within 7 days before starting the study, or who require more than 10 mg of prednisone per day
• People with a brain lesion that needs immediate treatment, including lesions in locations where growth or swelling could be dangerous (such as the brain stem)
• People with a known, symptomatic condition where cancer cells have spread to the fluid surrounding the brain and spinal cord
• People with poorly controlled seizures

Important: Always verify eligibility with the trial site directly before applying.